Abstract:Subsequently to the publication of the above article, an interested reader drew to the authors' attention that a pair of data panels featured between Figs. 4 and 7 contained overlapping data such that the data were derived from the same original source where they were intending to depict the results from experiments performed under different experimental conditions, and a pair of the data panels featured in Fig. 8 for the β‑catenin data also appeared to show overlapping data. The authors were able to re‑examine their original data, and have identified the data that were intended to have been shown for these figure parts. The corrected versions of Fig. 4 (showing the correct data for the LV‑DJ‑1/migration experiment in Fig. 4A), Fig. 7 (showing the correct data for the LV‑DJ‑1 + XAV939/migration experiment) and Fig. 8 (showing the correct data for the LV‑siRNA‑DJ‑1 experiment) are shown on the subsequent pages. The authors confirm that these inadvertent errors did not have any major impact on the conclusions reported in their paper, are grateful to the Editor of International Journal of Oncology for allowing them the opportunity to publish this Corrigendum, and apologize to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 56: 1115‑1128, 2020; DOI: 10.3892/ijo.2020.5005].

Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis

Correction: An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82

Corrigendum: YY1 Promotes Endothelial Cell-Dependent Tumor Angiogenesis in Hepatocellular Carcinoma by Transcriptionally Activating VEGFA

BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism

Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

Correction: EBV-miR-BART1-5P Activates AMPK/mTOR/HIF1 Pathway Via a PTEN Independent Manner to Promote Glycolysis and Angiogenesis in Nasopharyngeal Carcinoma

Correction To: KIF5B-RET Fusion Kinase Promotes Cell Growth by Multilevel Activation of STAT3 in Lung Cancer

Correction: A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination

Correction to: FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway

Correction to: Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma

Correction to: NUPR1 promotes the proliferation and metastasis of oral squamous cell carcinoma cells by activating TFE3-dependent autophagy

Author Correction: Reprogramming of palmitic acid induced by dephosphorylation of ACOX1 promotes β-catenin palmitoylation to drive colorectal cancer progression

Correction: PCDH1 promotes progression of pancreatic ductal adenocarcinoma via activation of NF-κB signalling by interacting with KPNB1

DJ‑1 Promotes Cell Proliferation and Tumor Metastasis in Esophageal Squamous Cell Carcinoma Via the Wnt/β‑catenin Signaling Pathway.

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Author Correction: ADH1C inhibits progression of colorectal cancer through the ADH1C/PHGDH /PSAT1/serine metabolic pathway

Correction: FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis

Correction: A Tissue Factor-Cascade-targeted Strategy to Tumor Vasculature: a Combination of EGFP-EGF1 Conjugation Nanoparticles with Photodynamic Therapy

Correction: Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance

Pin1: Advances in pancreatic cancer therapeutic potential and inhibitors research

Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma